Saltar al contenido principal
xMedica

NCT07919678ClinicalTrials.gov

A Study to Learn About Study Medicine Called Berobenatide in Adults With Knee Pain and Overweight or Obesity (VESPER-OA 1)

A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFICACY AND SAFETY OF ONCE-MONTHLY BEROBENATIDE IN ADULTS WITH KNEE OSTEOARTHRITIS AND OVERWEIGHT OR OBESITY (VESPER-OA 1)

En reclutamientoAdmite participantes ahora, según el registro.
Contactar con este estudio

En resumen

The purpose of this clinical study is to learn about the safety and effects of berobenatide (PF-08653944) for the treatment of knee osteoarthritis in adults with overweight or obesity. The study will last 52 weeks and compare the effects of…

Fase 3656 participantes buscados40 centros2 países

Categorías

Registrado en 1 registro

Un mismo estudio puede estar registrado en varios registros. Lo mostramos una sola vez y enlazamos con todos los registros que tenemos.

La información del ensayo se muestra tal como la publicó el registro, en su idioma original.

¿Le interesa este estudio?

Iniciar sesión o cree una cuenta para registrar su interés y seguir este estudio.

How this study is set up

The points below are drawn from the public registry record for this study. Each one cites the field or sentence it came from. A dash (—) means the record does not state something — not that it is missing or wrong. Many well-run studies, especially small ones, leave some of these blank.

  • Not stated: Registered after enrolment began (about 10 days after the recorded start)First posted 2026-11-05; recorded start 2026-10-26
  • Present: Has a defined primary outcomeA primary outcome measure is listed in the record
  • Present: The primary outcome states a time frameThe primary outcome measure records a time frame
  • Present: Participants are randomly assignedAllocation is recorded as randomised
  • Present: Has a comparison groupThe record lists a placebo or comparator arm, or more than one study arm
  • Present: Uses blinding (masking)A masking level is recorded in the record
  • Not stated: An ethics committee is not stated in the registry recordThis registry's ingested record has no ethics-committee field
  • Not stated: Regulatory oversight (such as an IND or IDE) is not stated in the registry recordThis registry's ingested record has no regulatory-authorisation field
  • Not stated: A data monitoring committee is not stated in the registry recordThis registry's ingested record has no data-monitoring-committee fieldA data monitoring committee is not required for many smaller studies, and its absence here is not unusual.
  • Present: No cost to participants is mentioned in the recordChecked the summary, description and eligibility text; no cost-to-participant phrase found
  • Present: Sponsor has 635 other studies in this databaseCounted from the lead sponsor named in the record (Pfizer)
  • Present: Sponsor has posted results for at least one studyBased on the sponsor’s studies in this database
  • The record lists 3 conditions.
  • Lead sponsor type recorded as: industry.
  • Intervention regulatory context: investigational, within a phased regulatory pathway.

Trial stature

Three independent measures of this study, described from its registry record — not a recommendation about it. A rigorous study by investigators nobody has heard of is better evidence than a weak study led by a famous one. How these are scored.

Methodological rigourDEFINITIVE

A definitive-grade design for a phase 3 study, judged from its ClinicalTrials.gov record.

How this score is built
  • Randomised allocation20/20

    Participants are randomly allocated between arms

  • Blinding20/20

    Quadruple-blind

  • Control arm13/15

    Placebo / sham control arm

  • Primary-outcome specificity10/10

    Named primary outcome with a defined time frame

  • Endpoint type3/10

    Surrogate or intermediate endpoint (conservative default)

  • Multi-centre8/8

    Multi-centre: 40 sites

  • Data monitoring committee7/7

    A data monitoring committee is in place

  • Prospective registration5/5

    Registered before the study start date

  • Protocol / SAP posted0/5

    No protocol or SAP posted to the registry

ScaleMEDIUM

A medium-sized study, international in scope: 656 participants (target), run at 40 sites, across 2 countries.

How this score is built
  • Enrolment28/40

    656 participants (target)

  • Site count19/25

    40 sites

  • Country count7/15

    2 countries

  • Planned duration7/10

    Planned over about 24 months

  • Sponsor scale10/10

    Pfizer has led 630 trials in our corpus

Investigator standingUNKNOWN

We have no verifiable track record for the investigator named on this trial. That is common for early-career investigators and for records held outside ClinicalTrials.gov — it is not a negative signal.

How this score is built
  • Investigator standing0/100

    No investigator recorded in the registry for this trial

These describe the registry record only, and today we hold ClinicalTrials.gov data. Absent fields lower a score, and absence often reflects registration practice rather than study quality. A high-stature trial is not necessarily safer or a better choice for you — enrolling in a large definitive trial can mean a higher chance of receiving placebo, while a small early-phase study may be the only route to a new therapy.

Resumen

The purpose of this clinical study is to learn about the safety and effects of berobenatide (PF-08653944) for the treatment of knee osteoarthritis in adults with overweight or obesity. The study will last 52 weeks and compare the effects of berobenatide compared to placebo on knee pain, physical function, and body weight. Study activities will include blood tests, knee pain assessment, physical function questionnaires and body measurements.

Afecciones

  • Obesity
  • Overweight
  • Osteoarthritis of the Knee

Elegibilidad

Elegibilidad
SexoTodos
Edades18 Years – Sin máximo
Voluntarios sanosNo

Elegibilidad tal como figura en el registro

Inclusion Criteria: * Adults 18 years of age or older, or the minimum age of consent according to local regulations. * Body mass index of at least 27 kg/m² at Screening. * Currently meets American College of Rheumatology (ACR) Criteria for knee OA. * Pain due to knee OA. * Knee radiograph consistent with knee osteoarthritis and Kellgren-Lawrence Grade 2 or 3. * Willingness to complete the required analgesic washout. * History of at least 1 self-reported unsuccessful dietary effort to lose body weight. Exclusion Criteria * Self-reported body weight increase or decrease greater than 5% within 90 days before Screening. * History of diabetes or Screening laboratory findings indicative of diabetes. * Known clinically significant gastric-emptying abnormality, history of acute or chronic pancreatitis, or active symptomatic gallbladder disease. * Personal history or first-degree family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2. * Significant active or unstable psychiatric disorder. * Condition or knee disorder that could confound assessment of target-knee pain. * Prior target-knee replacement, planned target-knee replacement, or planned elective knee surgery during the study. * Recent use of weight-loss medication, any glucose-lowering therapy, or other protocol-prohibited treatment. * Prior participation in a berobenatide clinical trial with receipt of active treatment or placebo. * Hypersensitivity to a drug with glucagon-like peptide-1 receptor activity, including berobenatide, or any excipient.

Elegibilidad en frases sencillas

Los criterios de este registro aún no se han desglosado en frases separadas. El texto del registro anterior está completo y es la versión autorizada.

Diseño del estudio

Diseño del estudio
Tipo de estudioDe intervención
FaseFase 3
AsignaciónAleatorizado
Modelo de intervenciónPARALLEL
Propósito principalTREATMENT
EnmascaramientoQUADRUPLE (4)
Inscripción656 participantes buscados

Patrocinador y colaboradores

  • Pfizer Patrocinador

Grupos e intervenciones

  • PlaceboPLACEBO_COMPARATOR

    Participants will receive placebo as subcutaneous injection

  • Arm 1: Berobenatide Once MonthlyEXPERIMENTAL

    Participants will receive berobenatide by subcutaneous injection.

  • Arm 2: Berobenatide Once MonthlyEXPERIMENTAL

    Participants receive berobenatide by subcutaneous injection.

  • Arm 3: Berobenatide Once MonthlyEXPERIMENTAL

    Participants receive berobenatide by subcutaneous injection.

Intervenciones

  • Fármaco Berobenatide

    Subcutaneous Injection

  • Otro Placebo

    Subcutaneous Injection

Variables de resultado

  1. Variable de resultado principal

    Change from baseline in Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Pain Subscale score

    Plazo Baseline and Week 52

  2. Variable de resultado secundaria

    Percent change from baseline in Body Weight

    Plazo Baseline and Week 52

  3. Variable de resultado secundaria

    Change From Baseline in High-Sensitivity C-Reactive Protein

    Plazo Baseline and Week 52

  4. Variable de resultado secundaria

    Change from baseline in WOMAC Physical Function Subscale score

    Plazo Baseline and Week 52

  5. Variable de resultado secundaria

    Percentage of participants with ≥50% reduction in the WOMAC pain subscale score

    Plazo Baseline and Week 52

  6. Variable de resultado secundaria

    Percentage of participants with ≥30% reduction in the WOMAC pain subscale score

    Plazo Baseline and Week 52

  7. Variable de resultado secundaria

    Proportion of participants with utilization of protocol specified pain medication during the washout period

    Plazo Baseline and Week 52

  8. Variable de resultado secundaria

    Amount of protocol specified pain medication during the washout period

    Plazo Baseline and Week 52

  9. Variable de resultado secundaria

    Change from baseline in WOMAC stiffness score

    Plazo Baseline and Week 52

  10. Variable de resultado secundaria

    Change from baseline in WOMAC total score

    Plazo Baseline and Week 52

  11. Variable de resultado secundaria

    Proportion of participants achieving ≥50% reduction in the WOMAC physical function subscale score

    Plazo Baseline and Week 52

  12. Variable de resultado secundaria

    Proportion of participants meeting OMERACT-OARSI

    Plazo Baseline and Week 52

  13. Variable de resultado secundaria

    Change from baseline in Average Pain Intensity-Numerical Rating Score

    Plazo Baseline and Week 52

  14. Variable de resultado secundaria

    Change from baseline in Worst Pain Intensity -Numerical Rating Score

    Plazo Baseline and Week 52

  15. Variable de resultado secundaria

    Change from baseline in SF-36 domain scales and component summary scales

    Plazo Baseline and Week 52

  16. Variable de resultado secundaria

    Change from baseline in Body Weight

    Plazo Baseline and Week 52

  17. Variable de resultado secundaria

    Change from Baseline in Body Mass Index

    Plazo Baseline and Week 52

  18. Variable de resultado secundaria

    Number of participants with Treatment Emergent Adverse Events (TEAEs)

    Plazo Baseline and Week 52

  19. Variable de resultado secundaria

    Number of Participants with Serious Adverse Events (SAE)

    Plazo Baseline and Week 52

  20. Variable de resultado secundaria

    Number of Participants with AE leading to permanent discontinuation from study intervention or study

    Plazo Baseline and Week 52

  21. Variable de resultado secundaria

    Number of Participants with Adverse Events of Special Interest (AESI)

    Plazo Baseline and Week 52

  22. Variable de resultado secundaria

    Number of Participants with Clinical laboratory abnormalities

    Plazo Baseline and Week 52

  23. Variable de resultado secundaria

    Change from baseline in timed walking distance at Week 52

    Plazo Baseline and Week 52

  24. Variable de resultado secundaria

    Percentage of Participants Reporting Improvement in Patient Global Impression of Severity (PGI-S) for knee-OA related physical function

    Plazo Baseline and Week 52

  25. Variable de resultado secundaria

    Percentage of Participants Reporting Improvement in Patient Global Impression of Severity (PGI-S) for knee-OA pain

    Plazo Baseline and Week 52

  26. Variable de resultado secundaria

    Percentage of Participants Reporting Improvement in Patient Global Impression of Change (PGI-C) for knee-OA related physical function

    Plazo Baseline and Week 52

  27. Variable de resultado secundaria

    Percentage of Participants Reporting Improvement in Patient Global Impression of Change PGI-C for knee-OA pain

    Plazo Baseline and Week 52

  28. Variable de resultado secundaria

    Change From Baseline in EuroQol 5-Dimension, 5-Level (EQ-5D-5L) Index Score

    Plazo Baseline and Week 52

  29. Variable de resultado secundaria

    Change From Baseline in EuroQol-visual analog scale (EQ-VAS) Score

    Plazo Baseline and Week 52

  30. Variable de resultado secundaria

    Change From Baseline in Work Productivity and Activity Impairment - General Health (WPAI:GH) Absenteeism Score

    Plazo Baseline and Week 52

  31. Variable de resultado secundaria

    Change From Baseline in WPAI:GH Work productivity loss score

    Plazo Baseline and Week 52

  32. Variable de resultado secundaria

    Change From Baseline in WPAI:GH Activity impairment score

    Plazo Baseline and Week 52

  33. Variable de resultado secundaria

    Change From Baseline in Systolic Blood Pressure (SBP)

    Plazo Baseline and Week 52

  34. Variable de resultado secundaria

    Change From Baseline in Diastolic Blood Pressure (DBP)

    Plazo Baseline and Week 52

  35. Variable de resultado secundaria

    Change From Baseline in Total Cholesterol

    Plazo Baseline and Week 52

  36. Variable de resultado secundaria

    Change From Baseline in High-density lipoprotein cholesterol (HDL-C)

    Plazo Baseline and Week 52

  37. Variable de resultado secundaria

    Change From Baseline in Low-density lipoprotein cholesterol (LDL-C)

    Plazo Baseline and Week 52

  38. Variable de resultado secundaria

    Change from baseline in Non-HDL Cholesterol

    Plazo Baseline and Week 52

  39. Variable de resultado secundaria

    Change from baseline in Very low-density lipoprotein cholesterol (VLDL) Cholesterol

    Plazo Baseline and Week 52

  40. Variable de resultado secundaria

    Change from baseline in Triglycerides

    Plazo Baseline and Week 52

Fechas

Fechas
Fecha de inicio26 de octubre de 2026 (real)
Finalización principal22 de agosto de 2028 (estimada)
Finalización10 de octubre de 2028 (estimada)
Primera publicación5 de noviembre de 2026 (real)
Última actualización5 de noviembre de 2026
Resultados publicadosNo indicado en el registro
Estado verificado por última vezoctubre de 2026

Real significa que el evento ocurrió. Estimada significa que el patrocinador lo prevé. Ambas cosas significan algo distinto.

Ubicaciones

7 centros están en reclutamiento

Canada

Canada
CentroCiudadEstado o regiónEstado
Bluewater Clinical Research Group Inc.SarniaOntarioAún no recluta

United States

United States
CentroCiudadEstado o regiónEstado
Albuquerque Clinical Trials, Inc.AlbuquerqueNew MexicoAún no recluta
Charlottesville Medical Research Center, LLCCharlottesvilleVirginiaAún no recluta
Northwestern University Feinberg School Of MedicineChicagoIllinoisAún no recluta
Great Lakes Clinical Trials, LLC dba Flourish ResearchChicagoIllinoisAún no recluta
Northwestern MedicineChicagoIllinoisAún no recluta
Northwestern Memorial Hospital, Diagnostic Testing Center (Phlebotomy/EKG)ChicagoIllinoisAún no recluta
Northwestern Memorial Hospital, Investigational Drug ServiceChicagoIllinoisAún no recluta
Clinical Research of West Florida, Inc.ClearwaterFloridaAún no recluta
Skylight Health ResearchColorado SpringsColoradoAún no recluta
Mercy Family ClinicDallasTexasAún no recluta
Universal Axon Clinical Research LLCDoralFloridaEn reclutamiento
Altoona Center For Clinical ResearchDuncansvillePennsylvaniaEn reclutamiento
Headlands Research California, LLCEscondidoCaliforniaAún no recluta
Profound Research LLCFarmington HillsMichiganEn reclutamiento
Cedar Health ResearchFort WorthTexasAún no recluta
Novant Health Granite Quarry Internal Medicine (knee x-ray)Granite QuarryNorth CarolinaAún no recluta
BRCR Global LouisianaGretnaLouisianaAún no recluta
JCCT-JUNO NW HoustonHoustonTexasAún no recluta
Westside Center for Clinical ResearchJacksonvilleFloridaAún no recluta
Activian Clinical ResearchKingwoodTexasAún no recluta
Renstar Medical ResearchLady LakeFloridaAún no recluta
Monroe Biomedical ResearchMonroeNorth CarolinaEn reclutamiento
AMR ClinicalNormanOklahomaAún no recluta
Renstar Medical ResearchOcalaFloridaAún no recluta
Prospective Research Innovations Inc.Rancho CucamongaCaliforniaAún no recluta
Accellacare - SalisburySalisburyNorth CarolinaAún no recluta
Consano Clinical Research, LLCShavano ParkTexasAún no recluta
Revive Research Institute, Inc.Sterling HeightsMichiganEn reclutamiento
Clinical Research AtlantaStockbridgeGeorgiaAún no recluta
Clinical Research of West Florida, Inc.TampaFloridaAún no recluta
AMR ClinicalTempeArizonaAún no recluta
DM Clinical ResearchTomballTexasAún no recluta
Solace Clinical ResearchTustinCaliforniaAún no recluta
Velocity Clinical Research, WacoWacoTexasAún no recluta
Elevate Clinical ResearchWichitaKansasAún no recluta
Delaney RadiologistWilmingtonNorth CarolinaEn reclutamiento
AccellacareWilmingtonNorth CarolinaEn reclutamiento
North Georgia Internal MedicineWoodstockGeorgiaAún no recluta
North Georgia Clinical Research, LLCWoodstockGeorgiaAún no recluta

Documentos del estudio

No hay documentos enlazados en este registro.

Cambios a lo largo del tiempo

No se han registrado cambios desde que incorporamos este registro por primera vez.

Se registra un cambio cada vez que el patrocinador actualiza el registro. El estado, las fechas, la inscripción y los centros aparecen aquí a medida que cambian.